Legend Biotech Corporation announced the appointment of Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development. Dr. Fang comes to Legend Biotech from Zymeworks Inc, where he served as senior vice president of Research and oversaw the development of novel platforms and a portfolio of multi-functional biologics and antibody drug conjugates. Dr. Fang will assume the responsibilities of Frank Fan, M.D., Ph.D., who resigned from the Company effective March 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.16 USD | -2.61% | +4.44% | -24.95% |
May. 15 | Legend Expects to Log Profit in 2026 | MT |
May. 14 | HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.95% | 8.23B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Biotech Corporation Announces Appointment of Guowei Fang as Global Head of Research and Early Development